Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

Riazi, 2022, The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 7, 851, 10.1016/S2468-1253(22)00165-0 Lazarus, 2021, Defining comprehensive models of care for NAFLD, Nat Rev Gastroenterol Hepatol, 18, 717, 10.1038/s41575-021-00477-7 Taylor, 2020, Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis, Gastroenterology, 158, 1611, 10.1053/j.gastro.2020.01.043 Francque, 2021, Non-alcoholic fatty liver disease: a patient guideline, JHEP Rep Innov Hepatol, 3 Davison, 2020, Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials, J Hepatol, 73, 1322, 10.1016/j.jhep.2020.06.025 Hardy, 2020, The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease, Contemp Clin Trials, 98, 10.1016/j.cct.2020.106175 Bedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002/hep.27173 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Nielsen, 2013, The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters, Am J Transl Res, 5, 303 Leeming, 2012, Enzyme-linked immunosorbent serum assay specific for the 7S domain of collagen type IV (P4NP 7S): a marker related to the extracellular matrix remodeling during liver fibrogenesis, Hepatol Res, 42, 482, 10.1111/j.1872-034X.2011.00946.x Sun, 2015, Collagen type III and VI turnover in response to long-term immobilization, PLoS One, 10, 10.1371/journal.pone.0144525 Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178 Boursier, 2018, Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH, Aliment Pharmacol Ther, 47, 1387, 10.1111/apt.14621 Cao, 2013, Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis, PLoS One, 8, 10.1371/journal.pone.0082092 Daniels, 2019, ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis, Hepatology, 69, 1075, 10.1002/hep.30163 Boyle, 2019, Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease, JHEP Rep Innov Hepatol, 1, 188, 10.1016/j.jhepr.2019.06.004 Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346 Guha, 2008, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers, Hepatology, 47, 455, 10.1002/hep.21984 Sanyal, 2022, Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease, J Hepatol Corey, 2022, ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD, J Hepatol, 76, 25, 10.1016/j.jhep.2021.09.026 Newsome, 2020, FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study, Lancet Gastroenterol Hepatol, 5, 362, 10.1016/S2468-1253(19)30383-8 DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 Obuchowski, 2004, ROC curves in clinical chemistry: uses, misuses, and possible solutions, Clin Chem, 50, 1118, 10.1373/clinchem.2004.031823 Brunt, 2022, Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD, J Hepatol, 76, 1030, 10.1016/j.jhep.2022.01.011 Harrison, 2020, A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study, Lancet Gastroenterol Hepatol, 5, 970, 10.1016/S2468-1253(20)30252-1 Noureddin, 2022, MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis, J Hepatol, 76, 781, 10.1016/j.jhep.2021.11.012 Nielsen, 2021, Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population, J Hepatol, 75, 1292, 10.1016/j.jhep.2021.08.016 Vali, 2020, Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis, J Hepatol, 73, 252, 10.1016/j.jhep.2020.03.036 Chuah, 2019, MACK-3 (combination of hoMa, Ast and CK18): a promising novel biomarker for fibrotic non-alcoholic steatohepatitis, Liver Int, 39, 1315, 10.1111/liv.14084 Lee, 2020, Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis, PLoS One, 15 Mulherin, 2002, Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation, Ann Intern Med, 137, 598, 10.7326/0003-4819-137-7-200210010-00011 Sanyal AJ, Shankar SS, Yates K, et al. Primary results of the nimble stage 1-NASH CRN study of circulating biomarkers for nonalcoholic steatohepatitis and its activity and fibrosis stage. AASLD Meeting; Nov 12–15, 2021 (suppl 1).